Screener
NewAmsterdam Pharma Company NAMS Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: NewAmsterdam Pharma Company’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333824
| Line item | For the six months ended June 30, 2026 | For the six months ended June 30, 2025 |
|---|---|---|
| Changes in accounts payable | (3,480) | 1,860 |
| Changes in accrued expenses and other current liabilities | (5,145) | (3,514) |
| Changes in deferred revenue | (1,190) | (6,008) |
| Net cash used in operating activities | (69,818) | (74,139) |
| Investing activities: | ||
| Purchase of property, plant and equipment, including internal use software | (118) | (104) |
| Maturities of marketable securities | 97,500 | 37,163 |
| Purchases of marketable securities | (113,653) | (193,340) |
Item 1. Financial Statements.
FAQ
- What is NewAmsterdam Pharma Company's operating cash flow?
- NewAmsterdam Pharma Company (NAMS) reported operating cash flow of -$39.21M in Q2 2026.
- How has NewAmsterdam Pharma Company's operating cash flow changed year-over-year?
- NewAmsterdam Pharma Company's operating cash flow decreased by 4.1% year-over-year, from -$37.67M to -$39.21M.
- What is the long-term trend for NewAmsterdam Pharma Company's operating cash flow?
- Over 4 years (2021 to 2025), NewAmsterdam Pharma Company's operating cash flow has grown at a 49.6% compound annual growth rate (CAGR), from -$29.51M to -$147.78M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about NewAmsterdam Pharma Company's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude